Vanguard Investments Australia
SYRE icon

Vanguard Investments Australia’s Spyre Therapeutics SYRE Stock Holding History

Vanguard Investments Australia’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Buy
14,752
+1,939
+15% +$141K ﹤0.01% 1116
2026
Q1 		$646K Buy
+12,813
New +$483K ﹤0.01% 1455

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Investments Australia's SYRE Position: Q2 2026 in Review

Vanguard Investments Australia increased its Spyre Therapeutics (SYRE) stake by 15% in Q2 2026, buying an estimated $141K and bringing the position to 14,752 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1116.

Vanguard Investments Australia first reported a position in SYRE in Q1 2026 and has held it in 2 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Vanguard Investments Australia held 14,752 shares of Spyre Therapeutics worth $1.31M as of Q2 2026.
  • Vanguard Investments Australia bought 1,939 Spyre Therapeutics shares in Q2 2026, an estimated $141K.
  • Spyre Therapeutics made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #1116 holding.
  • Vanguard Investments Australia first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.